Pharmaco-epidemiological Description of the Population Treated With Aptivus Under Market Conditions, Safety & Efficacy

Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals

NCT00034866 ·Status: COMPLETED ·Phase: PHASE2

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

NCT00146328 ·Status: COMPLETED ·Phase: PHASE2/PHASE3

Pharmacokinetics of Apricitabine and Tipranavir When Dosed Alone or Together

NCT00352066 ·Status: COMPLETED ·Phase: PHASE1

Safety Study of Tipranavir Co-administered With Low-dose Ritonavir (TPV/r) in Patients With Advanced HIV-1 Infection and Limited Treatment Options

NCT00144287 ·Status: COMPLETED ·Phase: PHASE3

Tipranavir Expanded Access Program (EAP) in PI-experienced Patients With HIV-1 Infection

NCT00097799 ·Status: APPROVED_FOR_MARKETING

A Randomised Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir (TPV) Plus 100 mg or 200 mg Ritonavir (RTV) p.o. BID in Comparison to 400 mg Lopinavir (LPV) Plus 100 mg RTV p.o. BID in Combination With Standard Background Regimen in ARV Therapy naïve Patients.

NCT00144105 ·Status: TERMINATED ·Phase: PHASE2

3 TPV/RTV Doses in Multiple ARV Experienced Patients - Tipranavir Dose Defining Study

NCT00275444 ·Status: COMPLETED ·Phase: PHASE2

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavir/r IN Race/Gender HIV+ Patients Randomized to TDM or SoC

NCT00440271 ·Status: TERMINATED ·Phase: PHASE3

Dual Boosted - Protease Inhibitor (PI) Pharmacokinetics (PK) Trial (Tipranavir / Ritonavir) in Highly Treatment-experienced HIV-1 Infected Patients

NCT00056641 ·Status: COMPLETED ·Phase: PHASE2

Safety and Acceptability Study of Non-occupational Prophylaxis (PEP) Following Potential Exposure to HIV

NCT01602822 ·Status: TERMINATED ·Phase: PHASE4

Nevirapine or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir in Human Immunodeficiency Virus (HIV)-1-infected Treatment Naive Adults

NCT00389207 ·Status: COMPLETED ·Phase: PHASE3

Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients With Tipranavir (RESIST)

NCT00054717 ·Status: COMPLETED ·Phase: PHASE3

Tipranavir and Ritonavir vs. Saquinavir and Ritonavir Used With Two Nucleoside Reverse Transcriptase Inhibitors in Single Protease Inhibitor-experienced HIV-1 Patients

NCT02239835 ·Status: TERMINATED ·Phase: PHASE2

Using Drug Levels and Drug Resistance Testing to Select Effective Anti-HIV Drug Combinations in Patients With Drug-resistant HIV

NCT00027339 ·Status: COMPLETED ·Phase: PHASE2

Study to Evaluate the Activity and Tolerability of Lopinavir/Ritonavir and Lamivudine Bitherapy in HIV Patients With Viral Suppression

NCT01471821 ·Status: COMPLETED ·Phase: PHASE4

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

NCT00135395 ·Status: COMPLETED ·Phase: PHASE3

Bictegravir in the Elderly Living With HIV (BICEP)

NCT05064020 ·Status: ACTIVE_NOT_RECRUITING

Study of the Efficacy and Safety of Apricitabine, a New NRTI, to Treat Drug-resistant HIV Infection

NCT00612898 ·Status: TERMINATED ·Phase: PHASE2/PHASE3

HIV-1 Infection Study of Once a Day Versus Twice a Day Protease Inhibitor in Antiretroviral Treatment Naive Adults

NCT00450580 ·Status: COMPLETED ·Phase: PHASE3

A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors

NCT00004580 ·Status: COMPLETED ·Phase: PHASE1

Boosted Atazanavir and Truvada Given Once-Daily - BATON Study

NCT00224445 ·Status: COMPLETED ·Phase: PHASE4

ATV/Ritonavir Nevirapine Interaction (USPAC)

NCT00162149 ·Status: COMPLETED ·Phase: PHASE1

Exploratory Study of Tipranavir and Ritonavir in Multiple Protease Inhibitor-experienced HIV Patients

NCT02238314 ·Status: COMPLETED ·Phase: PHASE2

Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.

NCT01237444 ·Status: COMPLETED ·Phase: PHASE3

Effects of Tipranavir/Ritonavir on the Pharmacokinetic Characteristics of Triple Drug Nucleoside and Non-nucleoside Reverse Transcriptase Inhibitor Therapy in HIV-1-infected Subjects

NCT02251223 ·Status: COMPLETED ·Phase: PHASE1/PHASE2